Announcements Trials
Browse Landscape

Phase

Phase 2 36Phase 3 31Phase 1/2 28Phase 1 20Phase 2/3 3Phase 4 2

Status

Completed 2

Sponsor Class

OTHER 7INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Thyroid Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × lenvatinib × Clear all
NCT03573960 2026-03-06

A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Eisai Inc.

Phase 4 Completed
50 enrolled
Head & Neck

Thyroid Neoplasms

NCT04297254 2023-11-15

A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

Eisai Inc.

Phase 4 Completed
50 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡